PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23123249-0	2013	Testing of novel brain-penetrating oxime reactivators of acetylcholinesterase inhibited by nerve agent surrogates.	Oximes	35-40	acetylcholinesterase	Rattus norvegicus	57-77	
23123249-1	2013	A critical need for combating the effects of organophosphate (OP) anticholinesterases, such as nerve agents, is the current lack of an effective oxime reactivator which can penetrate the blood-brain barrier (BBB), and therefore reactivate inhibited acetylcholinesterase (AChE) in the brain.	Oximes	145-150	acetylcholinesterase	Rattus norvegicus	249-269	
23123249-1	2013	A critical need for combating the effects of organophosphate (OP) anticholinesterases, such as nerve agents, is the current lack of an effective oxime reactivator which can penetrate the blood-brain barrier (BBB), and therefore reactivate inhibited acetylcholinesterase (AChE) in the brain.	Oximes	145-150	acetylcholinesterase	Rattus norvegicus	271-275	
23123249-4	2013	The oximes demonstrated a range of 14-76% reactivation of rat brain AChE in vitro.	Oximes	4-10	acetylcholinesterase	Rattus norvegicus	68-72	
23123249-5	2013	An in vivo testing paradigm was developed in which the novel oxime was administered at the time of maximal brain AChE inhibition (about 80%) (1h) elicited by nitrophenyl isopropyl methylphosphonate (NIMP; sarin surrogate).	Oximes	61-66	acetylcholinesterase	Rattus norvegicus	113-117	
23123249-6	2013	This paradigm, with delayed administration of oxime to a time when brain AChE was starting to recover, was designed to minimize reactivation/reinhibition of peripheral AChE during the reactivation period which would decrease the availability of the surrogate for entry into the brain; this paradigm will allow proof of concept of BBB penetrability.	Oximes	46-51	acetylcholinesterase	Rattus norvegicus	168-172